pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
LILLY · news · pharmadog
← back to LILLY
News mentioning LILLY
793
stories
Jun 9, 26
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
stat
Jun 8, 26
Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
stat
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 8, 26
STAT+: Novo underwhelmed by drug it once fought Pfizer for
stat
Jun 8, 26
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
stat
Jun 8, 26
#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot
endpoints
Jun 8, 26
STAT+: J&J spends $1 billion to enter KRAS race for cancer treatments
stat
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 8, 26
STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
stat
Jun 8, 26
Opinion: $2 million gene therapy cures require a financing model
stat
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 6, 26
STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
stat
Jun 6, 26
STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
stat
Jun 5, 26
Study data convince Lundbeck to push new migraine drug forward
biopharma dive
Jun 5, 26
STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
stat
Jun 4, 26
STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
stat
Jun 4, 26
STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
stat
Jun 4, 26
Lilly, Boehringer retrench in Germany on proposed health spending cuts
endpoints
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 4, 26
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
biopharma dive
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
Jun 3, 26
What it will take for more employer GLP-1 coverage
endpoints
Jun 3, 26
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
biopharma dive
Jun 3, 26
STAT+: Legend Biotech emerged as a rare market winner
stat
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 3, 26
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
endpoints
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 3, 26
Senior NIH scientist, research fellow charged with bringing deactivated mpox virus into U.S.
stat
Jun 2, 26
Lilly gives hospitals deadline to comply with 340B claims data policy
endpoints
← prev
page 23 of 27
next →
